Clamart, France, 07 March 2025 – MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, received CE mark approvals under the new Medical Device Regulation (MDR – 2017/745) for its android remote monitoring application, SmartView Connect™ App Mobile, allowing pacemaker, Implantable Cardiac Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) patients to stay seamlessly connected with their cardiology clinics. Following this milestone, the SmartView Connect™ App Mobile is now beginning its commercial rollout in selected countries across Europe.
The SmartView Connect™ App Mobile, available for Android Operating System smartphones, securely communicates with all compatible MicroPort® CRM Bluetooth®-enabled devices. This app ensures healthcare professionals receive the information they need for accurate diagnoses and effective patient care. The mobile app is designed to securely and wirelessly send device data to the MicroPort® CRM SmartView™ network eliminating the need for a dedicated bedside monitor. Its robust security features include encryption and access restrictions, offering patients and clinics peace of mind regarding data protection and transmission safety.
“Our goal is to leverage technology to make cardiac care more accessible and efficient” said Vincent Leveaux, Vice President Product Development and Operations at MicroPort® CRM. “The SmartView Connect™ App Mobile represents a significant step forward, enabling implantable pacemakers and defibrillators to securely and seamlessly connect with the everyday devices patients rely on, like their smartphones”
SmartView Connect™ App Mobile features: Connectivity status, transmission history, battery longevity, device information and educational videos. The app is available for download on Google Play.
About MicroPort® CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with global headquarters in Clamart, near Paris, France and an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853). With over 60 years of expertise and innovations, MicroPort® CRM develops, manufactures and commercializes cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally. These state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe.
More information is available at www.microport.com.
About Cardiac Pacemakers
Cardiac pacemakers are implanted in patients with an abnormally low heart rate (bradycardia), preventing them from leading a normal life. They are implanted under the skin, in the chest area, and are connected to the heart by transvenous leads that conduct electrical impulses to pace the heart and restore a normal heart rhythm. Patients implanted with a pacemaker must be regularly monitored by their cardiologist to ensure that the pacing system is working correctly.
About Implantable Cardiac Defibrillators (ICD)
Implantable Cardiac Defibrillators (ICDs) are for use in patients with a high risk of sudden cardiac death, continuously monitoring the heart rate and helping to regulate fast and potentially life-threatening electrical problems with the heart. ICDs are connected to the heart by one or two leads, including a defibrillation lead that passes through the veins. ICDs provide pacing bursts to stop sustained ventricular tachycardia (fast heart rate), as well as ‘back up’ pacing in case of bradycardia (slow heart rate). They also deliver high-energy shocks through the defibrillation lead to restore a normal rhythm within seconds when the electrical activity of the heart deteriorates into ventricular fibrillation.
About Cardiac Resynchronization Therapy (CRT)
CRT therapy is indicated in heart failure patients with cardiac desynchronization. The CRT devices are implanted under the skin, in the chest area, and are connected to the heart by three transvenous pacing leads that conduct electrical impulses to pace the heart. The pacing leads are positioned in the right atrium, right ventricle and left ventricle. The electric stimulation of the cardiac chambers triggering their contractions is synchronized in order to restore a better pumping efficiency of the heart. The CRT therapy has been demonstrated to improve survival and quality of life, and to reduce hospitalization in heart failure patients.